7884 Report 2010 Report 2010 02 06 2010 17:39 Page 34 34 Directors and governance BTG plc Annual Report and Accounts 2010 Board of directors Dr John Brown Chairman John Brown, PhD, MBA, FRSE, joined the Board of BTG in January 2008 and was appointed non-executive Chairman in March 2008.
He is the Chairman of the Nomination Committee.
John is Chairman of Axis-Shield plc and a non-executive director of Vectura Group plc.
He is Chairman of the Roslin Foundation and a non-executive director of the Technology Strategy Board.
Until late 2003, John was Chief Executive of Acambis plc.
He is a Fellow of the Royal Society of Edinburgh Committees and an Honorary Professor of the University of Edinburgh.
Nomination Committee Dr Louise Makin Chief Executive officer Louise Makin joined BTG as Chief Executive officer in October 2004 and she is a non-executive director of Premier Foods plc.
From 2001, she was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East.
Louise joined Baxter Healthcare in 2000 as Vice President, Strategy & Business Development Europe.
Before joining Baxter, she was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles at ICI between 1985 and 1998.
Louise has an MBA, and holds an MA in Natural Sciences and a PhD in Metallurgy from the University of Cambridge.
Rolf Soderstrom Chief Financial officer Rolf Soderstrom, BA, ACA, joined BTG as Chief Financial officer in December 2008 from Protherics PLC, where he was Finance Director from August 2007.
From 2004, he was a Divisional Finance Director of Cobham plc, managing a portfolio of businesses across Europe and the US.
From 2000 he was a Director of Corporate Finance at Cable & Wireless plc.
Prior to this, he worked in the Corporate Recovery and Corporate Finance Department of  after qualifying as a Chartered Accountant.
Professor Colin Blakemore Non-executive director Colin Blakemore FMedSci, Hon FSB, Hon FRCP, FRS, joined BTG as a non-executive director in October 2007.
Colin has been a Professor in the Medical School at Oxford University since 1979.
He was Chief Executive officer of the Medical Research Council from 2003 to 2007, and from 1996 to 2003 he was Director of the MRC Centre for Cognitive Neuroscience at Oxford.
He is a past President of the British Neuroscience Association, the Physiological Society, the Biosciences Federation now the Society Committees of Biology and the British Association for the Advancement of Science.
Colin Remuneration Committee studied Medical Sciences at Cambridge and completed a PhD at the University Audit Committee of California in Berkeley.
7884 Report 2010 Report 2010 02 06 2010 17:40 Page 35 35 Directors and governance BTG plc Annual Report and Accounts 2010 William James OShea Non-executive director Jim OShea joined BTG as a non-executive director in April 2009.
He is a director of Surface Logix Inc and CombinatoRx Inc and is a former Chairman of the US National Pharmaceuticals Council.
From 2007 to 2008, he was Vice Chairman of Sepracor, Inc, where he was also President and Chief Operating officer from 1999 to 2007.
Previously Jim was Senior Vice President of Sales & Marketing and Medical Affairs for Zeneca Pharmaceuticals US, a business unit of Zeneca Inc.
While at Zeneca, Committees he held several management positions of increasing responsibility in international Remuneration Committee sales and marketing in the US and the UK.
Nomination Committee Peter Chambr Non-executive director Peter Chambr joined BTG as a non-executive director in September 2006.
Peter is Chairman of both Axellia Pharmaceuticals AS and 7TM Pharma A S. He is also a non-executive director of Spectris plc, the precision instrumentation and controls company.
Peter was Chief Executive officer of Cambridge Antibody Technology Group plc from 2002 until its acquisition by AstraZeneca plc in 2006.
Previously he was Chief Operating officer of Celera Genomics Group and Chief Executive Committees of Bespak plc.
Remuneration Committee Nomination Committee Dr William Jenkins Non-executive director William Jenkins MA, Msc, MD, FRCP E joined BTG as a non-executive director in 2002 and is Chairman of the Remuneration Committee.
He is also a non-executive director at Eurand N. V. Consort Medical plc.
William was previously Head of Clinical Development & Regulatory Affairs for Novartis Pharma AG, having held the same position pre-merger from 1992 with CIBA-Geigy AG.
From 1988 he was Head of Global Clinical Research at Glaxo.
Since 1999 he has been Committees a consultant to pharmaceutical companies and to investment companies in the life Remuneration Committee sciences sector.
He gained MA and MD degrees from the University of Cambridge Audit Committee and his earlier career was in medical research at the Royal Postgraduate Medical School and later as a Senior Lecturer at the Royal Free Hospital, University of London.
Giles Kerr Non-executive director Giles Kerr joined BTG as a non-executive director in October 2007 and is Chairman of the Audit Committee.
Giles is currently the Director of Finance with the University of Oxford, UK.
He is also a Director of Victrex plc, Elan Corporation plc and Isis Innovation Ltd.
Previously Giles was the Group Finance Director and Chief Financial officer of Amersham plc, acquired by GE Healthcare in 2004.
Prior to his role at Amersham, he was a partner with Arthur Andersen in the UK.
He is a graduate Committees of the University of York and a Fellow of the Institute of Chartered Accountants Nomination Committee in England and Wales.
